Paul D. Rennert
@PDRennert
Followers
6K
Following
4K
Media
2K
Statuses
20K
Co-founder, President & CSO, Aleta Biotherapeutics, https://t.co/vyLXDleOdp - Founder & Principal, SugarCone Biotech, commentary at https://t.co/nE18E8qx8B
Holliston, MA
Joined December 2012
0
9
0
0
5
0
If clinical data like these hold up you have a nice race: autologous CAR-T leading (have to extend the lead: heme cancer "cures", and move to solid tumors), in vivo showing well (still heme cancers, also early AID), will need DOR results, allogeneic trying to find a way. .
14 patients with B cell cancers and 1 with autoimmune disease were treated with allogeneic anti-CD19 CAR T cells edited for immune evasion (TRAC/B2M/CIITA KD + CD47 overexpression), following lymphodepletion. @Sana_Biotech
2
1
8
RT @PDRennert: @BowTiedBiotech We also have to consider that there is a distinction between LV contemplated for oncology use, and LNP conte….
0
1
0
and now FDA grants iza-bren breakthrough designation in previously treated advanced EGFR-mutated NSCLC. #SystImmune $BMY .
prnewswire.com
/PRNewswire/ -- SystImmune Inc. (SystImmune), a clinical-stage biotechnology company, and Bristol Myers Squibb (NYSE: BMY) today announced that the U.S. Food...
0
0
1
smart list.
Reading between the lines : 5 R&D Priorities Under Howard Chang $AMGN. 1️⃣ Unlock the dark genome – Target non-coding DNA & lncRNAs like Xist for autoimmune B-cell reset. 2️⃣ Genetics + real-world data – Double success odds by validating targets via deCODE-scale human genomics.
0
0
1
target prosecution like this bispecific is a delicate dance between hoped-for efficacy and avoided toxicity . the EGFRxHER3 pair is a good choice. Why? see .
sugarconebiotech.com
A post-ASCO update on tumor targets DLL3, B7H3 and HER3 July 2025 Paul D Rennert, SugarCone Biotech LLC Introduction: DLL3, B7H3 and HER3 are compelling tumor antigens to target with cancer therape...
1
0
3
A very interesting bispecific ADC highlighted today by @JacobPlieth -while this discussion is focused on lung cancer, the first approval for iza-bren likely in nasopharyngeal carcinoma $BMY #SystImmune.
oncologypipeline.com
2
0
28
'Heat Wave' seems likely to become an antiquated weather term in New England . like 'Indian Summer' and 'January Thaw'.
0
0
1
RT @chuminhua432: 🇨🇳 #CTTQ released the first phase 2 clinical trial data of its HER2 bispecific #ADC, #TQB2102, for the treatment of NSCLC….
0
2
0
RT @chuminhua432: 🇨🇳 #GenFleet Therapeutics announced that the latest clinical trial data for its small-molecule KRAS G12D inhibitor, #GFH3….
0
8
0
RT @bradloncar: I’m back in Boston and later today will be recording the first episode of ‘Biotech Direct’. This will be @BiotechTV’s new r….
0
1
0
0
12
0
